Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Neostigmine and Glycopyrrolate via Iontophoresis
NCT04027972Phase 1Completed
- Sponsor
- James J. Peters Veterans Affairs Medical Center
- Start
- Mar 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of neostigmine and glycopyrronium in neurogenic bowel (NBD), sponsored by James J. Peters Veterans Affairs Medical Center. Primary endpoint: Serum concentrations of Neostigmine and Glycopyrrolate. Started Mar 2020; status: completed.
02
Drugs
neostigmineglycopyrronium
03
Conditions
neurogenic bowel (NBD)
Beyond the preview
Go deeper on NCT04027972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04027972.